The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
Abstract
CONTEXT: Limited data exist regarding use of drug-eluting stents outside of approved indications in real-world settings. OBJECTIVES: To determine the frequency, safety, and effectiveness of drug-eluting stents for off-label (restenosis, bypass graft lesion, long lesions, vessel size outside of information for use recommendation) and untested (left main, ostial, bifurcation, or total occlusion lesions) indications in percutaneous coronary intervention (PCI). DESIGN, SETTING, AND PATIENTS: Observational, prospective, multicenter registry to evaluate in-hospital, 30-day, and 1-year outcomes among patients undergoing PCI between January and June 2005 in 140 US academic and community medical centers. Of 7752 PCI-treated patients, 6993 (90%) received drug-eluting stents; of these, 5851 (84%) received no other devices. Standard, off-label, and untested use was determined in 5541 (95%) of these 5851 patients, constituting the study cohort. MAIN OUTCOME MEASURES: Frequency of off-label and untested use, 1-year repeat target vessel revascularization, and composite of death, myocardial infarction (MI), or stent thrombosis at in-hospital follow-up and during 1 year of follow-up. RESULTS: Of 5541 patients receiving drug-eluting stents, 2588 (47%) received stents for off-label or untested indications. Adjusted in-hospital risk of death, MI, or stent thrombosis was not statistically different with off-label or untested vs standard use. At 30 days, the risk of this composite end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.24-3.48; P = .005) but not untested use (adjusted HR, 1.45; 95% CI, 0.79-2.67; P = .23). Excluding early events, this end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P = .57) or untested use (adjusted HR, 0.91; 95% CI, 0.60-1.38; P = .66). At 1 year, compared with standard use, significantly higher rates of target vessel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P = .005) and untested use (adjusted HR, 1.49; 95% CI, 1.10-2.02; P = .01), although absolute rates were low (standard, 4.4% [n = 113]; off-label, 7.6% [n = 95]; untested, 6.7% [n = 72]). CONCLUSIONS: In contemporary US practice, off-label and untested use of drug-eluting stents is common. Compared with standard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower with both off-label and untested use. However, the absolute event rates remain low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Self-citationIakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Schofer, J., Schlüter, M., Gershlick, A. H., Wijns, W., Garcia, E., Schampaert, E., & Breithardt, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14462-5 · Cited by 955
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eisenstein, E. L., Anstrom, K. J., Kong, D. F., Shaw, L. K., Tuttle, R. H., Mark, D. B., Kramer, J. M., Harrington, R. A., Matchar, D. B., Kandzari, D. E., et al. (2007) · JAMA · doi:10.1001/jama.297.2.joc60179 · Cited by 870
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O’Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000127110.49192.72 · Cited by 759
Schampaert, E., Cohen, E. A., Schlüter, M., Reeves, F., Traboulsi, M., Title, L. M., Kuntz, R. E., & Popma, J. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.01.024 · Cited by 575
Lemos, P. A., Serruys, P. W., van Domburg, R. T., Saia, F., Arampatzis, C. A., Hoye, A., Degertekin, M., Tanabe, K., Daemen, J., Liu, T. K. K., et al. (2004) · Circulation · doi:10.1161/01.cir.0000109138.84579.fa · Cited by 543
Urban, P., Gershlick, A. H., Guagliumi, G., Guyon, P., Lotan, C., Schofer, J., Seth, A., Sousa, J. E., Wijns, W., Berge, C., et al. (2006) · Circulation · doi:10.1161/circulationaha.104.532242 · Cited by 322
Ardissino, D., Cavallini, C., Bramucci, E., Indolfi, C., Marzocchi, A., Manari, A., Angeloni, G., Carosio, G., Bonizzoni, E., Colusso, S., et al. (2004) · JAMA · doi:10.1001/jama.292.22.2727 · Cited by 314
Cited by
Chiu, J.-J., & Chien, S. (2011) · Physiological Reviews · doi:10.1152/physrev.00047.2009 · Cited by 2,280
Windecker, S., Serruys, P. W., Wandel, S., Buszman, P., Trznadel, S., Linke, A., Lenk, K., Ischinger, T., Klauss, V., Eberli, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61244-1 · Cited by 653
Garg, S., & Serruys, P. W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.007 · Cited by 501
Wiviott, S. D., Braunwald, E., McCabe, C. H., Horvath, I., Keltai, M., Herrman, J.-P. R., Van de Werf, F., Downey, W. E., Scirica, B. M., Murphy, S. A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60422-5 · Cited by 453
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone, G. W., Lansky, A. J., Pocock, S. J., Gersh, B. J., Dangas, G., Wong, S. C., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810116 · Cited by 443
Metadata
- Authors
- Beohar, N., Davidson, C. J., Kip, K. E., Goodreau, L., Vlachos, H. A., Meyers, S. N., Benzuly, K. H., Flaherty, J. D., Ricciardi, M. J., Bennett, C. L., & Williams, D. O.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-05-09
- Volume
- 297
- Issue
- 18
- Pages
- 1992
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1977267157
- Cited by
- 270
- References
- 18
- FWCI
- 49.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents. https://app.cochat.ai/papers/10.1001/jama.297.18.1992
- The paper
- Beohar, N., Davidson, C. J., Kip, K. E., Goodreau, L., Vlachos, H. A., Meyers, S. N., Benzuly, K. H., Flaherty, J. D., Ricciardi, M. J., Bennett, C. L., & Williams, D. O. (2007). Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents. JAMA. https://doi.org/10.1001/jama.297.18.1992
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.